Pfizer Announced Positive Phase 3 Results For Etrasimod In Ulcerative Colitis Patients
Pfizer announced positive Phase 3 results for etrasimod in moderately to severely active ulcerative colitis patients The study met the primary endpoint of the ELEVATE 12 study showing statistically significant improvement in clinical remission at week 12 with etrasimod (2 mg OD) vs placebo Statistically significant improvements were achieved in all secondary endpoints and safety […]
Pfizer Announced Positive Phase 3 Results For Etrasimod In Ulcerative Colitis Patients Read More ยป